Efficacy and safety of the first commercially available intracameral mydriatic and anaesthetic during cataract surgery

Session Details

Session Title: Cataract
Session Date/Time: Saturday 11/02/2017 | 08:30-11:00
Paper Time: 10:30
Venue: Auditorium 1

First Author: R.Haughney UK
Co Author(s): J. Sniatecki  S. Srinivasan              

Abstract Details

Purpose:

To evaluate the efficacy and safety of the first commercially launched intracameral mydriatic and anaesthetic mixture comprising of standardized combination of 0.02 % tropicamide, 0.31 % phenylepherine and 1 % lidocaine (Mydrane, Laboratories Th�a, Clermont � Ferrand, France) during cataract surgery.

Setting:

University Hospital Ayr, Ayr, Scotland, United Kingdom

Methods:

93 eyes of 93 subjects undergoing cataract surgery received 200 ?L of Mydrane following the first side port incision during cataract surgery. The time taken for pupil dilation following Mydrane injection and total surgical time were recorded. A caliper was used to measure the size of the intraoperative pupil size at three intraoperative time gates: immediately following Mydrane injection, following injection of Ophthalmic viscosurgical device (OVD) and at the end of cataract surgery. The main outcome measures were time taken for pupil dilation, maintenance of mydriasis during the procedure and the need for any other measures to maintain mydriasis.

Results:

There were no intraoperative or postoperative complications. A median intraoperative pupil size of 6 mm (range 5 to 8) was achieved following Mydrane administration. A median time of 27 seconds (range 18 - 44) was taken to achieve this. Following administration of Mydrane and OVD a median pupil size of 7.5 mm (range 6-9) was achieved. A median pupil size of 6.5 mm (range 3 � 9) was maintained during the cataract surgery procedure. No patients in this cohort required any additional methods or devices to maintain intraoperative mydriasis. The median surgical time was 14.0 minutes (range 9 to 30).

Conclusions:

Mydrane appears to be safe and effective in initiating and maintaining intraoperative mydriasis during cataract surgery. None of the subjects in this cohort required any additional modalities to maintain intraoperative mydriasis.

Financial Disclosure:

None